Reduced in vivo hepatic proteome replacement rates but not cell proliferation rates predict maximum lifespan extension in mice

Airlia C. S. Thompson,¹,‡,† Matthew D. Bruss,¹,‡ John C. Price,²,¶ Cyrus F. Khambatta,² William E. Holmes,² Marc Colangelo,¹,†,§ Marcy Dalidd,¹,§ Lindsay S. Roberts,¹ Clinton M. Astle,³ David E. Harrison³ and Marc K. Hellerstein¹,²

¹Department of Nutritional Science and Toxicology, University of California at Berkeley, Berkeley, CA 94720, USA
²KineMed Inc., Emeryville, CA 94608, USA
³The Jackson Laboratory, Bar Harbor, ME 04609, USA

Summary

Combating the social and economic consequences of a growing elderly population will require the identification of interventions that slow the development of age-related diseases. Preserved cellular homeostasis and delayed aging have been previously linked to reduced cell proliferation and protein synthesis rates. To determine whether changes in these processes may contribute to or predict delayed aging in mammals, we measured cell proliferation rates and the synthesis and replacement rates (RRs) of over a hundred hepatic proteins in vivo in three different mouse models of extended maximum lifespan (maxLS): Snell Dwarf, calorie-restricted (CR), and rapamycin (Rapa)-treated mice. Cell proliferation rates were not consistently reduced across the models. In contrast, reduced hepatic protein RRs (longer half-lives) were observed in all three models compared to controls. Intriguingly, the degree of mean hepatic protein RR reduction was significantly correlated with the degree of maxLS extension across the models and across different Rapa doses. Absolute rates of hepatic protein synthesis were reduced in Snell Dwarf and CR, but not Rapa-treated mice. Hepatic chaperone levels were unchanged or reduced and glutathione S-transferase synthesis was preserved or increased in all three models, suggesting a reduced demand for protein renewal, possibly due to reduced levels of unfolded or damaged proteins. These data demonstrate that maxLS extension in mammals is associated with improved hepatic proteome homeostasis, as reflected by a reduced demand for protein renewal, and that reduced hepatic protein RRs hold promise as an early biomarker and potential target for interventions that delay aging in mammals.

Key words: calorie restriction; cell proliferation; maximum lifespan extension; proteome dynamics; rapamycin; Snell Dwarf.

Introduction

Age is a risk factor for numerous diseases including cancer, diabetes, and neurodegenerative diseases (Miller, 2002). The potential social and economic consequences of the predicted increase in the proportion of the US population that is 65 years and over (West et al., 2014) have sparked great interest in the development of interventions that extend healthspan, the time in which an individual remains active and in good health. The extension of maximum lifespan (maxLS, generally defined as the age at which 90% of individuals in a given population have died) has proven to be a useful outcome metric, as it in principle represents a general slowing of the aging process rather than the curing of one specific age-related disease.

Over the last 50 years, several dietary, genetic, and pharmacological interventions have been identified that extend maxLS in laboratory animals, including mice (Weindruch et al., 1986; Liang et al., 2003; Miller et al., 2005; Harrison et al., 2009, 2014). Understanding the molecular underpinnings of the aging process and the biochemical pathways affected by interventions that attenuate the development of age-related diseases is a high priority. In particular, identifying metrics of biological processes, or biomarkers (BMs), that are involved in the slowing of aging in laboratory mammals will be essential for guiding the future development of interventions to extend human healthspan.

To identify such processes that play an etiologic role in age-related disease, our approach has been to test potential flux-based BMs of maxLS extension. This is an approach our group has previously applied to identify causal pathway BMs in other conditions, such as neurodegeneration (Fanara et al., 2012), fibrotic disease (Decaris et al., 2015), and cancer (Messmer et al., 2005). The concept underlying this strategy is that the activity of a metabolic process is best characterized by the molecular flux rate traversing the pathway and that changes in the flux rates of metabolic processes that play a causal role in the functional alterations of the condition may manifest earlier and more sensitively than static pathologic changes or complex clinical outcomes. Optimally, the functional role and measurement technique for these molecular processes will be translatable into human studies.

This rate-based BM approach may be particularly promising in combination with what is currently the most robust program for testing proposed interventions for extension of maxLS in mammals: the National Institute on Aging’s (NIA) Interventions Testing Program (ITP; Miller et al., 2007). These studies are the current gold standard for evaluating changes in lifespan (LS) in genetically heterogeneous mice but are time- and resource-intensive, limiting the number of interventions that can be...
tested each year. An initial screening strategy based on a panel of early BMs of maxLS extension could be used to further refine which candidate interventions should be prioritized for inclusion into LS studies in mice. This represents an attractive approach for identifying interventions with the potential to extend human healthspan.

No previous studies have identified robust and early BMs of maxLS extension applicable across diverse genetic backgrounds and interventions. Here, we used stable-isotope mass spectrometric measurement tools to screen for BMs based on the activity of targeted physiologic pathways believed to be involved in the aging process. These measurements were performed in three different yet well-established mouse models of maxLS extension, each on a different genetic background and each at relatively early time points in the LS of the model. The three models evaluated were Snell Dwarf mice, which are homozygous for a loss-of-function mutation in the Pit1 gene involved in anterior pituitary development; calorie-restricted (CR) mice, in which calories are reduced without malnutrition; and mice treated with rapamycin (Rapa), a macrolide that inhibits the serine/threonine kinase mechanistic target of rapamycin (mTOR; Blackwell et al., 1995; Flurkey et al., 2002; Harrison et al., 2009; Miller et al., 2011, 2013). Our broad objective was to identify early rate-based BMs of maxLS extension that meet several criteria, including that they (i) manifest soon after the initiation of an intervention; (ii) are predictive of maxLS extension at early time point measurements; (iii) are not sex-, strain- or intervention-specific, and (iv) reveal the activity (i.e., flux) of targeted biological pathways. In the studies presented here, we evaluated two candidate BMs of maxLS extension: reduced in vivo cell proliferation rates across multiple cell types and reduced in vivo proteome turnover rates.

A reduction in cell proliferation rates has been hypothesized to contribute to maxLS extension by inhibiting the promotional phase of carcinogenesis and delaying cellular replicative senescence (de Magalhães & Faragher, 2008). Consistent with this hypothesis, CR in rodents results in dramatic reductions in global cell proliferation rates as well as the preservation of the proliferative capacity of many cell types later in life (Lok et al., 1990; Wolf et al., 1995; Bruss et al., 2011). In contrast, premature aging and shortened maxLS are associated with early-life hyperproliferation and premature loss of the proliferative capacity of cells in both mice and humans (Pendergrass et al., 1993; Bridger & Kill, 2004).

A reduction in protein synthesis rates or slowing of protein replacement rates (RRs) (turnover) might in principle reflect preserved proteome homeostasis (proteostasis), which normally declines with age (Rattan, 2010). Proteostasis is achieved through the proper coordination of the synthesis, folding, transport, modification, and degradation of proteins. The maintenance of proteostasis requires translational fidelity, molecular chaperones to facilitate protein folding and the efficient detection, repair and, if necessary, replacement of misfolded and/or damaged proteins that might otherwise compromise cellular function. A reduction in protein synthetic burden may preserve proteostasis by limiting the accumulation of misfolded and/or damaged proteins, possibly by increasing translational fidelity, chaperone capacity, and/or proteolytic capacity (Hipkiss, 2007; Kapahi et al., 2010; Conn & Qian, 2013; Sherman & Qian, 2013). In addition, when global protein synthesis is inhibited, differential translational upregulation of mRNAs encoding proteins involved in somatic maintenance and stress responses has been reported (Yamasaki & Anderson, 2008; Kapahi et al., 2010). Conversely, a primary reduction in damage to proteins, induction of chaperone synthesis, or a primary increase in proteolytic capacity (i.e., improved editing) could improve proteostasis independently of the absolute rate of protein synthesis in tissues.

Consistent with the model that alterations in protein synthesis and proteostasis play roles in LS determination, numerous models of LS extension in yeast, worms, flies, and mice are characterized by reduced signaling and/or expression of machinery involved in protein synthesis as well as enhanced expression of factors involved in somatic maintenance and stress responses (McElwee et al., 2007; Harrison et al., 2009; Kennedy & Kaebeler, 2009). Conversely, impaired protein quality control results in features of premature aging and shortened LS in mice (Min et al., 2008).

Accordingly, the goal of the work presented here was to test the hypothesis that reduced cell proliferation rates, reduced protein synthesis rates, reduced protein RRs (prolonged half-lives), or other proteome alterations are early BMs of maxLS extension in mice. In all three models, we measured the in vivo proliferation rates of epidermal, liver, and mammary cells, as well as the in vivo RRs, relative pool sizes (RPS), and within-proteome absolute synthesis rates of over a hundred hepatic proteins across multiple gene ontologies.

Results

A reduction in vivo cell proliferation rates is not an early biomarker of maxLS extension in mice

To determine the extent to which a reduction in cell proliferation may be an early BM of maxLS extension in mice, we measured changes in the in vivo proliferation rates of epidermal, liver, and mammary cells in Snell Dwarf, CR, and Rapa-treated mice. These cell types were chosen because they have previously revealed sensitive, dose-dependent reductions in proliferation rates in response to CR regimens (Bruss et al., 2011 and data not shown).

In 6- to 7-month-old female Snell Het/Wt and Dwarf DW/J mice, proliferation rates of liver and mammary cells were significantly reduced in Snell Dwarf compared to Het/Wt mice (39.5% and 41.5% reduced, respectively). However, there was no difference in the proliferation rates of epidermal cells in Snell Dwarf compared to Het/Wt mice (Fig. 1A).

In 4-month-old female C57BL/6 mice after 6 weeks on either an AL or 25% CR diet, proliferation rates of epidermal, liver, and mammary cells were significantly reduced in CR compared to AL mice (57.4%, 52.2%, and 57.7% reduced, respectively), consistent with previous reports (Fig. 1B; Lok et al., 1990; Bruss et al., 2011).

In 8-month-old female UoHET3 mice after 4 months on either a control diet or a diet containing 14 ppm Rapa [Rapa (14 ppm)], there were no significant differences in the proliferation rates of any of the cell types between groups (Fig. 1C). This lack of any significant effect of Rapa treatment on the proliferation rates of any of these cell types contrasts with reports that Rapa reduces the proliferation rates of HepG2 liver cells in vitro and muscle cells in vivo (Varma & Khandelwal, 2007; Drake et al., 2013). Divergence from these previously published results may be explained by differences in the dose and method of Rapa administration, differences in the in vitro versus the in vivo effects of Rapa, or differences in cell types. However, our observation that the in vivo proliferation rate of liver cells was unchanged is consistent with a previous study that used a very similar experimental design (Drake et al., 2013).

The data from these three models provide evidence that reductions in the in vivo proliferation rates of the three cell types analyzed, although associated with maxLS extension in some settings, are not consistent across all models tested and, therefore, are not ideally suited as early BMs of maxLS extension in mice. It remains to be
Isotope Labeling in CR, and Rapa-treated mice. To capture changes in both the RR constants and relative protein concentrations in Snell Dwarf, early BMs of maxLS extension in mice, we measured protein synthesis or RRs (or other proteome alterations) may serve as biomarkers of maxLS extension in mice.

A reduction in in vivo hepatic proteome RRs may be an early biomarker of maxLS extension in mice

To determine the extent to which a broad, proteome-wide reduction in protein synthesis or RRs (or other proteome alterations) may serve as early BMs of maxLS extension in mice, we measured in vivo hepatic proteome dynamics and relative protein concentrations in Snell Dwarf, CR, and Rapa-treated mice. To capture changes in both the RR constants (k, fraction new protein per day) and RPS of individual proteins, we determined whether the proliferation rates of other cell types may serve as such BMs.

**Snell Dwarf model**

Hepatic proteomic analyses were conducted in 5.5- to 7-month-old female Snell Het/WT and Dwarf DW/J mice. We determined k values for 126 proteins, RPS values for 141 proteins, and WPASR values for 70 proteins in both Het/WT and Dwarf mice. Defining a change as plus or minus 10% of control value (Price et al., 2012b), k values were reduced for almost all (97.6%) of the identified proteins, while no proteins had increased k values in Snell Dwarf compared to Het/WT mice. RPS values were reduced for 35.5% and increased for 40.4% of the identified proteins in Snell Dwarf compared to Het/WT mice. Moreover, WPASR values were reduced for 86.0% and increased for only 10.0% of the identified proteins in Snell Dwarf compared to Het/WT mice (Fig. 2A–C, Table 1, and Spreadsheet S1). Both the mean hepatic proteome RR and mean WPASR were profoundly and significantly reduced in Snell Dwarf compared to Het/WT mice (mean ratio of Dwarf k to Het/WT k: 0.612; and mean ratio of Dwarf WPASR to Het/WT WPASR: 0.689; Fig. 3A,D and Table 1). These findings are consistent with reports of reduced translation initiation signaling and reduced rates of protein synthesis and replacement for mixed hepatic proteins, as measured by [4-3H]-phenylalanine incorporation, in Snell Dwarf compared to WT mice (Bates & Holder, 1988; Hsieh & Papaconstantinou, 2004).

**CR model**

Hepatic proteomic analyses were conducted in 18-month-old male C57BL/6 mice after 14 months on either an AL or 40% CR diet. Data from some of these AL and CR mice were reported previously (Price et al., 2012b); however, the data presented here include an additional heavy water labeling time point (2 days) as well as new SILAM analyses. We determined k values for 98 proteins, RPS values for 242 proteins, and WPASR values for 84 proteins in both AL and CR mice. Values of k were reduced for 60.2% and increased for only 1.0% of the identified proteins in CR compared to AL mice. RPS values were reduced for 38.0% and increased for 19.8% of the identified proteins in CR compared to AL mice. WPASR values were also reduced for 72.6% and increased for only 4.8% of the identified proteins in CR compared to AL mice (Fig. 2D–F, Table 1, and Spreadsheet S1). Both the mean hepatic proteome RR and mean WPASR were significantly reduced in response to CR (mean ratio of CR k to AL k: 0.867; and mean ratio of CR WPASR to AL WPASR: 0.833; Fig. 3B,E and Table 1). These results are consistent with a recent

---

Figure 1: In vivo cell proliferation rates. Fractional replacement rates (k, expressed as % newly divided cells per day) of epidermal, liver, and mammary cells in A) Snell Het/WT vs. Dwarf (n = 5–6 per group), B) AL vs. CR (n = 5–6 per group), and C) control vs. Rapa (14 ppm) mice (n = 5–12 per group). Values are expressed as mean ± SEM. Student's unpaired two-tailed t-tests were used for all between-group analyses (***p < 0.005, ****p < 0.0008).
\[ k = \ln \left( \frac{1 - f}{1 - t} \right) \]

\[ \text{RPS} = L:H \]

\[ \text{WPASR} = k_n \times \frac{\text{RPS}_n}{\text{RPS}_{\text{control}}} \]

**Fig. 2** In vivo RR (k), RPS, and WPASR values for individual hepatic proteins. Protein RRs (k, expressed as % new per day), relative pool sizes (RPS), and within-proteome absolute synthesis rates (WPASR) of hepatic proteins in A–C) Snell Het/WT vs. Dwarf, D–F) AL vs. CR, and G–I) control vs. Rapa (14 ppm) mice (n values per protein per parameter are provided in Spreadsheet S1). For each model, each vertical pair of solid and open symbols represents the mean RR (k), RPS, or WPASR value for an individual protein in the control and experimental group, respectively. For clarity, protein names are not listed and proteins are sorted in descending order based on control group values. J) Equation used to calculate RR (k), where \( f \) is the fraction of protein newly synthesized during the labeling period (as measured by deuterium incorporation) and \( t \) is the number of days of heavy water labeling. K) Equation used to calculate RPS, where L is the abundance of the light version of a given protein coming from control or experimental animals and H is the abundance of the heavy version of that same protein coming from the internal heavy SILAM standard. L) Equation used to calculate WPASR, where \( n \) represents either the control or experimental group.

**Table 1** Summary of global in vivo hepatic proteome alterations

| Model          | Mean  | # of proteins for which data were collected for parameter | # of proteins with ≥10% reduction in parameter (%) | # of proteins with ≥10% increase in parameter (%) |
|----------------|-------|----------------------------------------------------------|--------------------------------------------------|-----------------------------------------------|
| Snell Dwarf    | 0.612 | 126 141 70                                               | 123 (97.6%) 50 (35.5%) 60 (86.0%)                  | 0 (0.0%) 57 (40.4%) 7 (10.0%)                 |
| CR             | 0.867 | 98 242 84                                               | 59 (60.2%) 92 (38.0%) 61 (72.6%)                  | 1 (1.0%) 48 (19.8%) 4 (4.8%)                  |
| Rapa (14 ppm)  | 0.946 | 270 254 199                                             | 88 (32.6%) 26 (10.2%) 49 (24.6%)                  | 28 (10.4%) 81 (31.9%) 55 (27.7%)              |

Experimental refers to the longer-lived group within each model [Snell Dwarf, CR, or Rapa (14 ppm)], and control refers to the control group within each model (Snell Het/WT, AL, and control, respectively). \( k \) = protein replacement rate (expressed as % new protein per day). RPS, relative pool size; WPASR, within-proteome absolute synthesis rate. Rapa (14 ppm) data from Rapa proteomics study 1.
Slower protein turnover predicts extended lifespan, A. C. S. Thompson et al.

### Study Employing Short-Term (10 Weeks) 40% CR in Older Mice (25-Month-Old)

Using heavy-leucine labeling, these authors observed a ~33% reduction in hepatic protein RRs in CR compared to AL mice (Karunadharma et al., 2015).

### Rapa Treatment Model

Hepatic proteomic analyses were initially conducted in 8-month-old female UM-HET3 mice after 4 months on either a control diet or a Rapa (14 ppm) diet. We determined k values for 270 proteins, RPS values for 254 proteins, and WPASR values for 199 proteins in both control and Rapa (14 ppm) mice. Values of k were reduced for 32.6% and increased for 10.4% of the identified proteins in Rapa (14 ppm) compared to control mice. RPS values were reduced for 10.2% and increased for 31.9% of the identified proteins in Rapa (14 ppm) compared to control mice. The percentage of identified proteins that exhibited a reduction in WPASR in Rapa (14 ppm) compared to control mice was very similar to the percentage that were increased, with 24.6% exhibiting a reduction in WPASR and 27.7% exhibiting an increase (Fig. 2G–I, Table 1, and Spreadsheet S1). Mean hepatic proteome RR (k) and WPASR values. Hepatic protein RRs (k) in A) Snell Het/WT vs. Dwarf (n = 126 proteins), B) AL vs. CR (n = 98 proteins), and C) control vs. Rapa (14 ppm) mice (n = 270 proteins). Within-proteome absolute synthesis rates (WPASR) of hepatic proteins in D) Snell Het/WT vs. Dwarf (n = 70 proteins); E) AL vs. CR (n = 84 proteins), and F) control vs. Rapa (14 ppm) mice (n = 199 proteins). Values are expressed as mean ± SEM. Paired two-tailed heteroscedastic t-tests were used for all between-group analyses (***P < 0.0001). Rapa (14 ppm) data from Rapa study 1.

### Taken Together, These Results Identify the Primary Common Global Hepatic Proteome Alteration in All Three Models to Be a Significant Reduction in Protein RRs (Fig. 3A–C). A Reduction in in vivo Hepatic Protein RRs (prolonged half-lives), but not overall absolute protein synthesis rates, may therefore be an early BM of maxLS extension in mice. Importantly, this reduction in protein RRs cannot be explained by a simple reduction in cell proliferation rates. Specifically, the absolute differences in protein replacement between control and experimental groups were of a much greater magnitude (8.5%/d, 2.8%/d, and 1.1%/d) compared to the absolute differences in cell RRs (0.23%/d, 0.26%/d, and 0.02%/d) for the Snell Dwarf, CR, and Rapa models, respectively. Additionally, it is unlikely that rapidly replaced proteins and/or a specific subclass of proteins biased our observations, as proteins with far-ranging RRs involved in a wide range of biological processes were captured (k value range: 1.7–72% new per day; Spreadsheet S1).

### Additional Common Hepatic Proteome Alterations that were Observed in all Three Models Included a Reduction in the WPASRs of Proteins Involved in Protein Processing in the Endoplasmic Reticulum (ER) and a Preservation or Increase in the WPASRs of Glutathione S-transferases (GSTs) Relative to all other Proteins (Figs S1 and S2). Western blot analysis revealed that chaperone levels were either unchanged or reduced in all three models (Fig. S3).

By comparing the 54 proteins for which we derived RR data in all three models, we found a significant correlation between the degree of maxLS extension and the degree of hepatic protein RR reduction. The degree of hepatic protein RR reduction was smallest in response to 14 ppm Rapa treatment, which is established to extend maxLS by 12%, and greatest in Snell Dwarf mice, which live 40% longer than their Het/WT counterparts, while hepatic protein RRs were reduced to an intermediate level in response to 40% CR, which extends maxLS by...
18% (Fig. 4) (Blackwell et al., 1995; Flurkey et al., 2002; Harrison et al., 2002, 2011, 2013). These data suggest that a reduction in hepatic protein RRs may be an early BM not only qualitatively of maxLS extension but also quantitatively of the degree of maxLS extension in mice. Interestingly, the significant correlation between the degree of maxLS extension and the degree of hepatic protein RR reduction was maintained even when all proteins identified in each model were considered, not just those commonly identified in all three models (Fig. S4).

To test this hypothesis further, we measured changes in hepatic protein RRs in response to three different doses of Rapa. A recent ITP study found that Rapa treatment extends maxLS in mice in a dose-dependent manner at doses of 4.7 and 14 ppm but that there is no additional extension of maxLS at 42 ppm relative to 14 ppm (Fig. 5A; Miller et al., 2013). The question that we specifically addressed here was whether changes in hepatic protein RRs were predictive of the degree of maxLS extension at these different doses of Rapa and would therefore plateau at 14 ppm. We found that hepatic protein RRs were reduced in a dose-dependent manner at the 4.7 and 14 ppm doses (reaching statistical significance only at the 14 ppm dose) but that there was no additional reduction in hepatic protein RRs at 42 ppm relative to 14 ppm (Fig. 5B and Spreadsheet S1). These dose-response data provide additional evidence that a reduction in hepatic protein RRs may be a quantitative correlate and BM of the degree of maxLS extension in mice.

A correlation is also apparent between k and %mean or medianLS extension across the three models, but the effect of Rapa is greater than that of CR on %mean or medianLS extension while being less than that of CR on k, and the correlation is not statistically significant (Fig. S5). Moreover, the plateau dose–response of Rapa on k at >14 ppm is not mirrored by a plateau effect on %mean or medianLS extension (Fig. S6).

Accordingly, a statistically significant quantitative relationship has been demonstrated here between k and %maxLS extension but not between k and %mean or medianLS extension.

**Discussion**

The major findings of this work are as follows: (i) A reduction in hepatic proteome RRs (longer half-lives) is a common feature of all three models evaluated (Snell Dwarf, CR, and Rapa-treated mice); (ii) a strong correlation exists between the degree to which hepatic proteome RRs are reduced and the degree of maxLS extension in these models; and (iii) in vivo cell proliferation rates are not consistently reduced at early time points in all these models.

The first observation could have more than one underlying cause. We do not believe that our data suggest that a reduction in hepatic proteome RRs is an initiating factor that directly promotes maxLS extension in the three models evaluated here. Rather, our hypothesis is that reduced hepatic proteome RRs reflect a reduced demand for protein renewal, and thus improved proteostasis in these models, likely due to reduced levels of misfolded and/or damaged proteins. The data presented here differentiate between several potential mechanisms of improved hepatic proteostasis in these models. In principle, a variety of cellular adaptations could reduce the levels of misfolded and/or damaged proteins, including an increase in proteolytic editing capacity, an increase in chaperone capacity, a reduction in the levels of damaging metabolites, or an increase in translational fidelity. The data presented here are not consistent with increased proteolytic editing as a major contributing factor to improved proteostasis, as reduced rather than increased proteome RRs (proteolytic rates) were consistently observed in all three models. We also found that the levels of the chaperones that
Slower protein turnover predicts extended lifespan, A. C. S. Thompson et al.

Fig. 5 Effects of different doses of Rapa on maxLS and mean in vivo hepatic protein RRs (k). A) Rapa dose (ppm) vs. % maxLS extension (adapted from Miller et al., % maxLS in response to Rapa (14 ppm) represents mean of % maxLS extensions reported in Miller et al., 2011, 2013) and B) Rapa dose (ppm) vs. mean hepatic protein RR (k; expressed as % new per day). A total of 150 proteins were identified in all four dosage groups (n values for each protein are provided in Spreadsheet S1). Values are expressed as mean ± SEM. A repeated-measures ANOVA with Tukey’s post hoc test was used to analyze between-dose differences (doses not sharing a letter are significantly different, P < 0.05). Data from Rapa study 2.

we assessed were either unchanged or reduced in all three models, suggesting that an increase in chaperone capacity is an unlikely contributing factor to improved proteostasis (Fig. S3). Consistent with improved proteostasis, as well as an absence of accumulated unfolded proteins in the ER in these three models, our proteomic analyses revealed that the synthesis of proteins involved in protein processing in the ER was reduced relative to the synthesis of all other proteins in the three models (Fig. S1).

While we did not directly measure protein damage or the levels of protein-damaging metabolites in the present studies, we did find that the only subset of related proteins that exhibited preserved or increased synthesis based on our proteomic analyses in all three models was glutathione S-transferases (GSTs; Fig. S2). GSTs play critical protective roles in cells by inactivating molecules capable of damaging various cellular components including proteins (Hayes et al., 2005). It is possible that improved proteostasis in the three models evaluated in our studies is related at least in part to reduced accumulation of damaged proteins by virtue of increased or preserved GST synthesis and function.

The levels of damaged and/or misfolded proteins in cells can also be reduced by increasing translational fidelity, as mistranslated proteins are more susceptible to becoming misfolded and damaged (Ballesteros et al., 2001). Translational fidelity can be increased by simply slowing down the rate of translation elongation (Conn & Qian, 2013; Sherman & Qian, 2013). While we did not directly measure elongation rates here, the possibility that elongation rates may be reduced in the models evaluated here is supported by the fact that inhibition of mTOR complex 1 (mTORC1) (a feature of all three models) in vitro reduces the rate of elongation and increases translational fidelity (Conn & Qian, 2013).

Karunadharma et al. (2015) recently published an elegant study that is highly complementary to the results presented here and provides mechanistic insights into improved proteostasis in two of the three models evaluated here. Using heavy-leucine labeling, this group found that 10 weeks of 40% CR in 25-month-old mice and 10 weeks of 14 ppm Rapa treatment in 3-month-old mice reduced hepatic protein RRs by 30% and 13%, respectively. Furthermore, they provided evidence of reduced hepatic protein damage in both CR and Rapa-treated mice and indirect evidence of reduced translation elongation rates in Rapa-treated (but not CR) mice. These data provide evidence that the reduction in hepatic protein RRs in CR and Rapa-treated mice is due to a reduced demand for protein renewal attributable to a reduction in protein damage, consistent with the model that we propose here. Reduced protein damage has been previously reported in Snell Dwarf mice relative to control counterparts (Flurkey et al., 2001); however, it remains to be determined whether elongation rates are reduced and translational fidelity is increased in these mice.

The observation that protein RRs (i.e., proteolytic clearance rates) are reduced in the three models evaluated is perhaps counterintuitive in light of reports of reduced mTORC1 signaling and enhanced autophagy in these models (Hsieh & Papaconstantinou, 2004; Wang & Miller, 2012; Fok et al., 2013). Autophagy is a lysosomal pathway that degrades various cellular components, including proteins and organelles, and is suppressed by mTORC1 signaling and upregulated in response to certain forms of stress, such as nutrient deprivation (Klionsky & Emr, 2000). Upregulation of autophagy would be expected to increase protein RRs, but we reproducibly measured a general reduction in hepatic proteome RRs in all three models. One possible explanation for this observation is that flux through the autophagic pathway is in fact not enhanced in these models, as many researchers rely on surrogate as opposed to direct measurements of autophagic flux.

It is important to note the limitations of the present study. First, our main conclusion that a reduction in hepatic protein RRs may serve as a BM of maxLS extension is based on the assessment of only three models. We believe that the formal validation of this putative BM is required in other models of maxLS extension. In particular, this putative BM should be tested in models that are not as intimately linked to reduced nutrient sensing and altered mTORC1 signaling as the three models assessed here. Given that maxLS can likely be extended via multiple mechanisms, we do not expect reduced hepatic protein RRs, or any other single BM, to manifest in response to all interventions that extend maxLS. A reduction in hepatic protein RRs might serve as one BM among a panel. Second, there was variability in the duration of heavy water labeling period in our studies. However, in all three models, proteins with a wide range of RRs were identified [2.1–72.4% in Snell Dwarf, 8.5–54.4% in CR, and 1.7–63.9% in Rapa (14 ppm)] across multiple gene ontologies, so a bias toward fast or slow turnover proteins or a functional class of proteins is not likely. Third, our main conclusion is based on the kinetic assessment of a modest number or proteins, and the data presented may be biased toward more abundant proteins in liver. Assessing the RRs of only a subset of hepatic proteins of relatively high abundance may, however, capture the key information regarding proteostasis in these settings. Lastly, there was variability in the age of assessment and duration of intervention. Importantly, all mice were assessed at or before reaching their half-maxLS. The duration of intervention was 21–27%, 40%, and 11% of maxLS in the Snell Dwarf, CR, and Rapa (14 ppm) models, respectively. Despite this variability, we observed a significant correlation between the degree of hepatic protein
RR reduction and maxLS extension at relatively early time points within the LS of each model. Moreover, demonstration of a dose–response relationship is generally considered a particularly strong class of supportive evidence in pharmacologic studies. Thus, the value of reduced hepatic protein RRs as a BM is bolstered by the Rapa dose–response study in which we observed that within a given model, a reduction in hepatic protein RRs is a strong and sensitive predictor of the degree of maxLS extension.

Overall, the data presented here demonstrate that a reduction in hepatic protein RRs meets at least 3 of the 4 criteria listed above for an early rate-based BM of maxLS extension, as this BM (i) manifests relatively soon after the initiation of each intervention (after 4–14 months of intervention, corresponding to 11–40% of total LS); (ii) is predictive of maxLS extension at early time point measurements; (iii) is not strain- or intervention-specific (three interventions were tested each on a unique genetic background) (although both sexes were not tested); and (iv) reveals the activity (i.e., flux) of a targeted biological pathway (proteome replacement).

As part of future efforts to continue to validate reduced hepatic protein RRs as a BM of maxLS extension, it will be important to determine whether a reduction in hepatic protein RRs predicts maxLS extension at earlier time points and in both sexes of the models presented here. A good test of the validity of this BM would be to determine whether it recapitulates the well-established sex-specific difference in the degree of maxLS extension in response to Rapa treatment.

Measuring hepatic protein RRs in response to interventions proven to have no effect on maxLS in mice, or only on meanLS, will also be necessary to determine the extent to which this putative BM is specific for maxLS extension and thus, potentially, a slowing of the aging process.

It is possible that the observed effect on proteome RRs in the liver in these three models manifests in other tissues, including blood plasma, which can be accessed relatively noninvasively. Translation of this BM approach in these models may therefore be possible by measuring plasma protein RRs, a technique already established in humans (Price et al., 2012a).

In summary, the quest to extend human healthspan requires the development of a panel of early and sensitive BMS of maxLS extension for prioritization of candidate interventions into large-scale healthspan and LS studies in mice. While further validation will be essential, the data presented here provide evidence that a reduction in global hepatic proteome RRs may serve as one such BM.

### Experimental procedures

#### Mice, animal husbandry, diets, feeding regimens, and duration of heavy water (D2O) labeling

Details regarding the published %maxLS extension, groups, strain, sex, age at initiation of intervention, duration of intervention, and duration of heavy water labeling for each model for each type of study can be found in Table 2. All other details regarding husbandry, diets, feeding regimens, and duration of heavy water labeling are presented in Supporting Information. All experiments were performed under the approval of the Institutional Animal Care and Use Committees of the University of California at Berkeley.

#### Heavy water labeling protocols

To measure rates of in vivo DNA synthesis and protein replacement, mice were labeled with an intraperitoneal injection of 100% D2O at the times specified in Table 2 prior to the end of each study. Mice were then

### Table 2 Summary of studies performed here and of previously reported studies

| Model                  | Type of intervention | Study  | Previously reported % maximum lifespan extension* | Groups                  | Strain (Sex) | Age at initiation of intervention | Duration of intervention | 2H2O label duration (days) | kDa range of proteins analyzed |
|------------------------|----------------------|--------|--------------------------------------------------|-------------------------|--------------|-----------------------------------|--------------------------|----------------------------|-------------------------------|
| Snell Dwarf            | Monogenetic†         | CP     | 40% (Flurkey et al., 2002)                       | Het/WT or Snell Dwarf   | DW/J (F)     | Birth                            | 6–7 months†             | 19                         | NA                            |
|                        |                      | P      | 40% (Flurkey et al., 2002)                       | Het/WT or Snell Dwarf   | DW/J (F)     | Birth                            | 5.5–7 months‡            | 1, 2, 4                    | 10–80                         |
| CR                     | Dietary              | CP     | ND                                               | AL or CR§              | C57BL/6 (F)  | 4 months                         | 6 weeks                  | 20                         | NA                            |
|                        |                      | P‡      | 18% (Blackwell et al., 1995)                     | AL or CR**             | C57BL/6 (M)  | 4 months                         | 14 months                | 1, 2, 4, 8, 15, 32          | 3.5–160                       |
| Rapa Treatment         | Pharmacological      | CP     | 12% (14 ppm) (Miller et al., 2011, 2013)‡†       | Control or Rapa        | UM-HET3 (F)  | 4 months                         | 4 months                 | 2‡§, 6, 18, 24              | 3.5–160                       |
|                        | and Rapa†            | P†      | 5% (4.7 ppm) (Miller et al., 2013)              | Control or Rapa        | UM-HET3 (F)  | 4 months                         | 4 months                 | 2                          | 20–40                         |
|                        | Rapa‡                | P†      | 11% (42 ppm) (Miller et al., 2013)‡            |                          |              |                                  |                          |                            |                               |

*Relative to control counterparts.
†Homozygous for loss-of-function recessive mutation in Pit1 gene.
‡Duration of intervention taken to be the age of the animals at the time of euthanasia.
§25% calorie-restricted relative to AL.
¶Adapted from (Price et al., 2012b).
**40% calorie-restricted relative to AL.
††Rapa proteomics study 1.
‡‡Mean of % maximum lifespan extensions reported in Miller et al. (2011, 2013).
§§2-day-labeled mice used for Rapa proteomics study 1.
¶¶Rapa proteomics study 2.
CP, cell proliferation; P, proteomics.
provided free access to 8% heavy water as drinking water for the remainder of the studies, as previously described (Bruss et al., 2011).

**LC-MS/MS analysis**

Details of LC-MS/MS analysis methods are presented in Supporting Information. Details regarding specific peptides and proteins identified and unique peptide coverage are presented in Spreadsheets S1 and S2.

**Calculation of fractional replacement (f), replacement rate constant (k), relative pool size (RPS), and within-proteome absolute synthesis rates (WPASR) for individual proteins**

Details of f calculations were previously described (Price et al., 2012a), and calculation of k, RPS, and WPASR values for individual proteins is presented in Supporting Information. Individual protein-level k, RPS, and WPASR data and individual peptide-level f and RPS data are presented in Spreadsheet S1.

**Statistical analyses**

Data were analyzed using GraphPad Prism software (version 5.0a) (La Jolla, CA, USA) and Real Statistics Resource Pack (http://www.real-statistics.com/free-download/real-statistics-resource-pack/) in Excel (2011).

All other experimental procedures are presented in Supporting Information.

**Acknowledgments**

The authors would like to thank Simplicia FlorCruz, Mark Fitch, Joan Protasio, and Chancy Fessler for their technical assistance. JCP and CFK were previously employed and WEH, MC, MD, and MKH are currently employed at KineMed Inc., Emeryville, CA 94608, USA.

**Author contributions**

ACST, MDB, JCP, CFK, DEH, and MKH conceived and designed experiments. ACST, MDB, JCP, CFK, DEH, and MKH contributed reagents/materials/analysis tools. ACST, MDB, JCP, CFK, DEH, and MKH contributed to writing the manuscript.

**Conflict of interest**

None declared.

**Funding**

This work was supported by NIH grant AG034297-01 and College of Natural Resources, University of California at Berkeley, support to MKH; funds from KineMed, Inc.; and NIH grants AG038560, AG022308, and AG032333 to DEH plus The Jackson Laboratory’s CA034196 (for work at TJL).

**References**

Ballesteros M, Fredriksson A, Henriksson J, Nyström T (2001) Bacterial senescence: protein oxidation in non-proliferating cells is dictated by the accuracy of the ribosomes. *EMBO J*. **20**, 5280–5289.

Bates PC, Holder AT (1988) The anabolic actions of growth hormone and thyroxine on protein metabolism in Snell Dwarf and normal mice. *J. Endocrinol.* **119**, 31–41.

Blackwell BN, Bucci TJ, Hart RW, Turturo A (1995) Longevity, body weight, and neoplasia in ad libitum-fed and diet-restricted C57BL/6 mice fed NIH-31 open formula diet. *Toxicol. Pathol.* **23**, 570–582.

Brider JM, Kill IR (2004) Aging of Hutchinson-Gilford progeria syndrome fibroblasts is characterised by hyperproliferation and increased apoptosis. *Exp. Gerontol.* **39**, 717–724.

Bruss MD, Thompson ACS, Aggarwal I, Khambatta CF, Hellerstein MK (2011) The effects of physiological adaptations to calorie restriction on global cell proliferation rates. *Am. J. Physiol. Endocrinol. Metab.* **300**, E735–E745.

Conn CS, Qian S-B (2013) Nutrient signaling in protein homeostasis: an increase in quantity at the expense of quality. *Sci. Signal.* **6**, ra24.

Decaris ML, Emson CL, Li K, Gatmaitan M, Luo F, Cattin J, Nakamura C, Holmes WE, Angel TE, Peters MG, Turner SM, Hellerstein MK (2015) Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease. *PLoS ONE* **10**, e0123311.

Drake JC, Peelor FF 3rd, Biela LM, Watkins MK, Miller RA, Hamilton KL, Miller BF (2013) Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. *J. Gerontol. A Biol. Sci. Med. Sci.* **68**, 1493–1501.

Fanara P, Wong P-YA, Husted KH, Liu S, Liu VM, Kohlstaedt LA, Riff T, Protasio JC, Boban D, Killion S, Killian M, Epling L, Sinclair E, Peterson J, Price RW, Cabin DE, Nussbaum RL, Brühmann J, Brandt R, Christine CW, Aminoff MJ, Hellerstein MK (2012) Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. *J. Clin. Invest.* **122**, 3159–3169.

Flurkey K, Papaconstantinou J, Miller RA, Harrison DE (2001) Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone signaling. *Proc. Natl Acad. Sci. USA* **98**, 6736–6741.

Flurkey K, Papaconstantinou J, Harrison DE (2002) The Snell Dwarf mutation P1t1 (dw) can increase life span in mice. *Mech. Ageing Dev.* **123**, 121–130.

Fok WC, Zhang Y, Salmon AB, Bhattacharya A, Gunda R, Jones D, Ward W, Fisher K, Richardson A, Pérez VI (2013) Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice. *J. Gerontol. A Biol. Sci. Med. Sci.* **68**, 108–116.

Garelick MG, Mackay VL, Yanaqida A, Academia EC, Schreiber KH, Ladies WC, Kennedy BK (2013) Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo. *Cell Cycle (Georgetown, TX)* **12**, 2493–2504.

Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter ES, Paehler M, Javors MA, Fernandez E, Miller RA (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* **460**, 392–395.

Harrison DE, Strong R, Allison DB, Amos BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, Nelson JF, Pletcher S, Simpkins JW, Smith D, Wilkinson JE, Miller RA (2014) Acarbose, 17a-estradiol, and norohydroguaiaretic acid extend mouse lifespan preferentially in males. *Aging Cell* **13**, 273–282.

Hayes JD, Flanagan JA, Jouveye IR (2005) Glutathione transfersases. *Annu. Rev. Pharmacol. Toxicol.* **45**, 51–88.

Hipkiss AR (2007) On why decreasing protein synthesis can increase lifespan. *Mech. Ageing Dev.* **128**, 412–414.

Hisea C-C, Papaconstantinou J (2004) Akt/PKB and p38 MAPK signaling, integrative biology insights from genes that regulate longevity. *Aging Cell* **3**, 282–290.

Karunadharma PP, Basisty N, Dai D-F, Chiao YA, Quarles EK, Hsieh EJ, Crispin D, Bielas JH, Ericson NG, Beyer RP, MacKay VL, MacCoss MJ, Rabinovitch PS (2015) Assessment of mitochondrial biogenesis and mTORC1 signaling during chronic rapamycin feeding in male and female mice. *J. Gerontol. A Biol. Sci. Med. Sci.* **68**, 1493–1501.

Kapahi P, Chen D, Rogers AN, Katewa SD, Li PM-L, Thomas EL, Kockel L (2010) With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. *Cell Metab.* **11**, 453–465.

Karunadharma PP, Basisty N, Dai D-F, Chiao YA, Quarles EK, Hsieh EJ, Crispin D, Bielas JH, Ericson NG, Beyer RP, MacKay VL, MacCoss MJ, Rabinovitch PS (2015) Subacute calorie restriction and rapamycin discordantly alter mouse liver proteome homeostasis and reverse aging effects. *Aging Cell* **14**, 547–557.

Kennedy BK, Kaeberlein M (2009) Hot topics in aging research: protein translation, 2009. *Aging Cell* **8**, 612–623.

Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. *Science* **290**, 1717–1721.

Liang H, Masoro EJ, Nelson JF, Strong R, McMahen CA, Richardson A (2003) Genetic mouse models of extended lifespan. *Exp. Gerontol.* **38**, 1353–1364.

Lok E, Scott FW, Jongeau R, Nera EA, Malcolm S, Clayson DB (1990) Calorie restriction and cellular proliferation in various tissues of the female Swiss Webster mouse. *Cancer Lett.* **41**, 617–623.

de Magalhães JP, Faragher RGA (2008) Cell divisions and mammalian aging: integrative biology insights from genes that regulate longevity. *BioEssays* **30**, 567–578.
Slower protein turnover predicts extended lifespan, A. C. S. Thompson et al.

McElwee JJ, Schuster E, Blanc E, Piper MD, Thomas JH, Patell DS, Selman C, Withers DJ, Thornton JM, Partridge L, Gems D (2007) Evolutionary conservation of regulated longevity assurance mechanisms. Genome Biol. 8, R132.

Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrari M, Zupo S, Cutrona G, Damle RN, Waisl T, Rai KR, Hellerstein MK, Chiorazzi N (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115, 755–764.

Miller RA (2002) Extending life: scientific prospects and political obstacles. Milbank Q. 80, 155–174.

Miller RA, Buehner G, Chang Y, Harper JM, Sigler R, Smith-Wheelock M (2005) Methionine-deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and stress resistance. Aging Cell 4, 119–125.

Miller RA, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, Javors MA, Leeuwenburgh C, Nelson JF, Ongini E, Nadon NL, Warner HR, Strong R (2007) An Aging Interventions Testing Program: study design and interim report. Aging Cell 6, 565–575.

Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Fletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 66, 191–201.

Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Fletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R (2007) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 6, 468–477.

Min J-H, Whaley RA, Sharpless NE, Lockyer P, Portbury AL, Patterson C (2008) CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol. Cell. Biol. 28, 4018–4025.

Pendergrass WR, Li Y, Jiang D, Wolf NS (1993) Decrease in cellular replicative potential in “giant” mice transfected with the bovine growth hormone gene correlates to shortened life span. J. Cell. Physiol. 156, 96–103.

Price JC, Holmes WE, Li KW, Floreani NA, Neese RA, Turner SM, Hellerstein MK (2012a) Measurement of human plasma proteome dynamics with 2H2O and liquid chromatography tandem mass spectrometry. Anal. Biochem. 420, 73–83.

Price JC, Khambatta CF, Li KW, Bruss MD, Shankaran M, Dalid M, Floreani NA, Roberts LS, Turner SM, Holmes WE, Hellerstein MK (2012b) The effect of long term calorie restriction on in vivo hepatic proteostasis: a novel combination of dynamic and quantitative proteomics. Mol. Cell Proteomics 11, 1801–1814.

Rattan SIS (2010) Synthesis, modification and turnover of proteins during aging. In Protein Metabolism and Homeostasis in Aging Advances in Experimental Medicine and Biology. (Tavernarakis N, ed.). New York, NY: Springer, pp 1–13.

Sherman MY, Qian S-B (2013) Less is more: improving proteostasis by translation slow down. Trends Biochem. Sci. 38, 585–591.

Varma S, Khandelwal RL (2007) Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB. Biochim. Biophys. Acta 1770, 71–78.

Wang M, Miller RA (2012) Fibroblasts from long-lived mutant mice exhibit increased autophagy and lower TOR activity after nutrient deprivation or oxidative stress. Aging Cell 11, 668–674.

Weindruch R, Walford RL, Fliegel S, Guthrie D (1986) The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J. Nutr. 116, 641–654.

West LA, Cole S, Goodkind D, He W (2014) 65+ in the United States: 2010. Washington, D.C., USA: U.S. Department of Health and Human Services.

Wolf NS, Penn PE, Jiang D, Fei RG, Pendergrass WR (1995) Caloric restriction: conservation of in vivo cellular replicative capacity accompanies life-span extension in mice. Exp. Cell Res. 217, 317–323.

Wu CC, MacCoss MJ, Howell KE, Matthews DE, Yates JR (2004) Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal. Chem. 76, 4951–4959.

Yamasaki S, Anderson P (2008) Reprogramming mRNA translation during stress. Curr. Opin. Cell Biol. 20, 222–226.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

Spreadsheet S1. GO terms, protein-level data and peptide-level data for each model.

Spreadsheet S2. Spectrum Mill protein identification details.

Fig. S1. Hepatic synthesis of proteins involved in protein processing in the ER (PPER).

Fig. S2. Hepatic synthesis of GST proteins.

Fig. S3. Chaperone levels in the liver.

Fig. S4. Correlation of % maxLS extension and change in hepatic protein replacement rates (k) across models.

Fig. S5. Correlation of % meanLS or % medianLS extension and change in hepatic protein replacement rates (k) across models.

Fig. S6. Effects of different doses of rapamycin on % medianLS and in vivo hepatic protein replacement rates (k).

Data S1. Additional experimental procedures.